In the realm of cholangiocarcinoma, Akihiko Kida et al.’s investigation into immune responses against TAA-derived CD8+ T-cell epitopes identified KIF20A among other TAAs as promising targets for immunotherapy. The gene discussed is KIF20A; the disease is cholangiocarcinoma.